Nexsen Limited operates as a nanobiotechnology company that develops proprietary biosensing platforms for rapid, high-precision point-of-care (POC) medical diagnostics and point-of-use sensing for veterinary, agricultural, and biosecurity applications. The company offers Group B Streptococcus (GBS) rapid sensor, a diagnostic for the detection of human GBS in expectant mothers; kidney diseases, a POC tests for the screening, detection, and ongoing monitoring of various subsets of acute kidney injury and chronic kidney disease; bovine mastitis, a farm diagnostic to detect mastitis early which helps farmers; biosecurity pathogen tests, a portable sensor for frontline detection of invasive pests and pathogens -built for customs officers, farmers, and quarantine zones. The company was incorporated in 2021 and is based in Sydney, Australia.
Metrics to compare | NXN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNXNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.0x | −6.9x | −0.5x | |
PEG Ratio | - | 0.02 | 0.00 | |
Price/Book | 4.4x | 3.6x | 2.6x | |
Price / LTM Sales | 36.5x | 14.3x | 3.1x | |
Upside (Analyst Target) | - | 141.1% | 53.1% | |
Fair Value Upside | Unlock | −3.6% | 7.1% | Unlock |